Alumis (ALMS) vs Jade Biosciences (JBIO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Jade Biosciences (JBIO) has outperformed Alumis (ALMS) over the past year, gaining 52.3% versus a gain of 50.1%. Alumis is the larger company by market cap ($905.4 million vs $885.9 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ALMS | JBIO |
|---|---|---|
| Share price | $7.00 | $13.93 |
| Market cap | $905.40M | $885.91M |
| 1-day change | +3.32% | +1.16% |
| YTD return | -30.64% | -10.76% |
| 1-year return | +50.11% | +52.32% |
| 5-year return | — | -97.22% |
| EPS (TTM) | $-3.86 | $-1.92 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $31.35 | $28.00 |
| 52-week low | $4.28 | $8.36 |
| Distance from 52-week high | -77.69% | -50.25% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +359.33% | +259.87% |
| Average volume | 2.43M | 888.66K |
| Shares outstanding | 129.44M | 63.60M |
| Employees | 237 | 55 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Alumis
ALMS stock →Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor that is in Phase 1 for the treatment of neuroinflammatory and neurodegenerative diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 237 employees
About Jade Biosciences
JBIO stock →Jade Biosciences, Inc. operates as a biotechnology company that develops therapies for inflammation and immunology indications in patients living with autoimmune diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 55 employees
ALMS vs JBIO FAQ
Which is bigger, Alumis or Jade Biosciences?
Alumis (ALMS) is larger, with a market capitalization of $905.40M compared with $885.91M for Jade Biosciences (JBIO).
Which stock has performed better over the past year, ALMS or JBIO?
JBIO returned +52.32% over the past 12 months, compared with +50.11% for ALMS (price return, excluding dividends). Past performance does not predict future results.
Are Alumis and Jade Biosciences in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.